StreetInsider.com News Articles

Form 8-K Xilio Therapeutics, Inc. For: Mar 12

Thu, 12 Mar 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260312/26149965.html

Form 8-K Xilio Therapeutics, Inc. For: Mar 12

Thu, 12 Mar 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260312/26149965.html

Xilio Therapeutics implements 1-for-14 reverse stock split

Thu, 12 Mar 2026 08:30:25 -0400

Xilio Therapeutics, Inc. (NASDAQ: XLO) will implement a 1-for-14 reverse stock split of its common stock effective at 5:00 p.m. Eastern Time on March 13, 2026. The clinical-stage biotechnology company announced the move aims to increase its per-share market price and regain compliance with Nasdaq Capital Market's minimum bid price requirement.

The reverse stock split received approval from stockholders at a special meeting held on February 23, 2026, with the board of directors determining the final ratio. Trading on a split-adjusted basis will begin when markets open on March 16, 2026, under the existing ticker "XLO" with new CUSIP number 98422T209.

The

Xilio Therapeutics Announces 1-for-14 Reverse Stock Split

Thu, 12 Mar 2026 08:30:00 -0400

WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that it will implement a 1-for-14 reverse stock split of the issued shares of the company’s common stock, effective at 5:00 p.m. Eastern Time on March 13, 2026.

The reverse stock split was approved by the company’s stockholders at the company’s Special Meeting of Stockholders held on February 23, 2026, with the final ratio subsequently determined by the company’s Board of Directors. One of the

Xilio Therapeutics Announces 1-for-14 Reverse Stock Split

Thu, 12 Mar 2026 08:30:00 -0400

Form 8-K Xilio Therapeutics, Inc. For: Mar 09

Mon, 09 Mar 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260309/26129200.html

Form 8-K Xilio Therapeutics, Inc. For: Mar 09

Mon, 09 Mar 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260309/26129200.html

Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Mon, 02 Mar 2026 08:00:00 -0400

WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that company management will participate in a fireside chat during the Leerink Partners Global Healthcare Conference on Monday, March 9, 2026 at 3:00 p.m. ET.

A live webcast can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at ir.xiliotx.com. A replay of the webcast will be archived on the website for 30 days following the

Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Mon, 02 Mar 2026 08:00:00 -0400

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 02 Mar 2026 07:30:00 -0400

WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective March 1, 2026, the company granted non-qualified stock options to purchase 50,050 shares of its common stock to two new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.

The stock options have an exercise price of $0.5283 per share, which is equal to the closing price of the company’s common stock on February 27, 2026. Each stock option has a ten-year term

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 02 Mar 2026 07:30:00 -0400

The stock options have an exercise price of $0.5283 per share, which is equal to the closing price of the company’s common stock on February 27, 2026. Each stock option has a ten-year term

Form 8-K Xilio Therapeutics, Inc. For: Feb 23

Tue, 24 Feb 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260224/26046763.html

Form 8-K Xilio Therapeutics, Inc. For: Feb 23

Tue, 24 Feb 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260224/26046763.html

Form 4 Xilio Therapeutics, Inc. For: Feb 13 Filed by: GILEAD SCIENCES, INC.

Tue, 17 Feb 2026 17:32:00 -0400

si-local-file:///var/storage/secattach/20260217/26015410.html

Form 4 Xilio Therapeutics, Inc. For: Feb 13 Filed by: GILEAD SCIENCES, INC.

Tue, 17 Feb 2026 17:32:00 -0400

si-local-file:///var/storage/secattach/20260217/26015410.html

Form SCHEDULE 13G/A Xilio Therapeutics, Inc. Filed by: Bain Capital Life Sciences Fund II, L.P.

Tue, 17 Feb 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260217/26013759.html

Form SCHEDULE 13G/A Xilio Therapeutics, Inc. Filed by: Bain Capital Life Sciences Fund II, L.P.

Tue, 17 Feb 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260217/26013759.html

Form SCHEDULE 13G/A Xilio Therapeutics, Inc. Filed by: STEMPOINT CAPITAL LP

Tue, 17 Feb 2026 10:00:00 -0400

si-local-file:///var/storage/secattach/20260217/26008564.html

Form SCHEDULE 13G/A Xilio Therapeutics, Inc. Filed by: STEMPOINT CAPITAL LP

Tue, 17 Feb 2026 10:00:00 -0400

si-local-file:///var/storage/secattach/20260217/26008564.html

Form SCHEDULE 13G/A Xilio Therapeutics, Inc. Filed by: Frazier Life Sciences Public Fund, L.P.

Fri, 13 Feb 2026 17:32:00 -0400

si-local-file:///var/storage/secattach/20260213/26002215.html

Form SCHEDULE 13G/A Xilio Therapeutics, Inc. Filed by: Frazier Life Sciences Public Fund, L.P.

Fri, 13 Feb 2026 17:32:00 -0400

si-local-file:///var/storage/secattach/20260213/26002215.html

Form 8-K Xilio Therapeutics, Inc. For: Feb 11

Thu, 12 Feb 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260212/25992999.html

Form 8-K Xilio Therapeutics, Inc. For: Feb 11

Thu, 12 Feb 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260212/25992999.html

Form 424B5 Xilio Therapeutics, Inc.

Thu, 12 Feb 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260212/25992962.html

Form 424B5 Xilio Therapeutics, Inc.

Thu, 12 Feb 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260212/25992962.html